Asset Details
Do you wish to reserve the book?
Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis
Do you wish to request the book?
Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis
2025
Overview
Background
Kidney involvement is frequent in SLE, with proliferative lupus nephritis (LN) forms and nephritic flares being key predictors of poor outcomes. Conflicting results have been reported for anti-C1q antibodies among the serological markers. Our purpose was to assess the value of immunological tests (C3,C4 complement fractions, anti-DNA and antiC1q antibodies) in predicting histological classes and flares of lupus nephritis (LN).
Methods
For histological class prediction, we evaluated the immunological tests performed on the day of kidney biopsy by linear and multiple regression analyses. For flare prediction, univariable and multivariable Cox analyses were made at baseline, 6, and 12 months.
Results
Of 61 participants in the study, 47 had proliferative (III, IV) and 14 non-proliferative LN (II, V) at kidney biopsy. In proliferative LN, anti-DNA (
p
= 0.0186) and anti-C1q antibodies (Ab) (
p
= 0.0050) were significantly higher, and serum C3 and C4 lower (
p
= 0.0026;
p
= 0.0212) compared to non-proliferative LN. At multiple regression analysis, the best association to differentiate proliferative from non-proliferative LN was the number of urinary erythrocytes (OR 3.2292; CI 1.2585–8.2858;
p
= 0.0148) and anti-C1qAb (OR 1.0288; CI 1.0016–1.0568;
p
= 0.0380). Of 53 patients evaluated for flare predictions, followed for 60.69 (37.20-78.704) months, 10 (18.86%) had a renal flare at 28.19 months (24.84–39.38, range:16.3–55.8) from therapy initiation. At univariable analysis, anti-C1qAb (
p
= 0.0340,
p
= 0.0005) and no-use hydroxychloroquine (
p
= 0.0313,
p
= 0.0276) predicted flares at baseline and six months. Anti-C1qAb (
p
= 0.0047), non-use hydroxychloroquine (
p
= 0.0252), anti-C1qAb
≥
40UA (
p
= 0.0047), 24/h proteinuria (
p
= 0.0185), and proteinuria
≥
0.5 g/day (
p
= 0.0216) predicted flares at 12 months. At multivariable analysis, anti-C1q > 40UA (OR 9.0721; CI 0.9146–42.9882;
p
= 0.0057) and non-use of hydroxychloroquine (OR 0.1742 CI 0.0445–0.6823;
p
= 0.0126) were the independent predictors of renal flares.
Conclusion
Immunological tests can differentiate proliferative from non-proliferative LN, but anti-C1qAb and urinary erythrocytes had the best predictive power. Only persistent high anti-C1qAb at 1 year and non-use of hydroxychloroquine seem to predict renal flares.
Publisher
BioMed Central,BioMed Central Ltd,BMC
